Mounjaro 10 mg is recommended for use in the following cases: 🔹 Type 2 Diabetes Mellitus: For patients requiring enhanced glycemic control when 5 mg or 7.5 mg doses are ineffective. 🔹 Weight Correction in Obesity: Prescribed to adults with a BMI ≥30 kg/m² or ≥27 kg/m² in the presence of complications (hypertension, dyslipidemia), when the goal is significant fat mass loss and improvement of overall health.

Dosage and administration

Sales Form: 1 multi-dose KwikPen (2.4 ml of solution) containing 4 doses of 10 mg.⚠️ INSTRUCTIONS FOR USE: Dosage Regimen: The drug is administered strictly once a week. The transition to the 10 mg dosage is carried out no earlier than after 4 weeks of using the 7.5 mg dose. Method of Administration: Subcutaneous injection into the abdomen, thigh, or upper arm. It is recommended to rotate injection sites weekly. Timing: The injection can be given at any time of day, regardless of meals. Storage Conditions: Store in the original packaging in the refrigerator at 2°C–8°C. Do not freeze! After starting use (first injection), the pen can be stored at room temperature up to 30°C for 21 days.

⛔ Medullary Thyroid Carcinoma: Personal or family history of this disease in the past. ⛔ Endocrine Pathologies: Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). ⛔ Pregnancy and Breastfeeding: Use of the drug is contraindicated. ⛔ Type 1 Diabetes: The drug is not intended for the treatment of insulin-dependent type 1 diabetes. ⛔ GI Diseases: Severe gastroparesis and other serious digestive disorders. ⛔ Age: Safety and efficacy for individuals under 18 years of age have not been established.

When using the 10 mg dosage, side effects may be more pronounced at the beginning of the course: 🤢 Gastrointestinal: Nausea, vomiting, diarrhea, or constipation. These symptoms are usually adaptive and resolve over time. 📉 Appetite Changes: Significant decrease in appetite, aversion to certain foods. 😴 General Condition: Possible drowsiness, increased fatigue, or headache. 💧 Dehydration Risk: If nausea and vomiting occur, it is important to consume enough fluids to protect the kidneys. ⚠️ Serious Complications (rare): Acute pancreatitis, gallbladder problems, hypoglycemia (when combined with insulin or sulfonylureas).

Mounjaro KwikPen 10 — Tirzepatide 10 mg, 1 pcs, Eli Lilly India

100% original product

Active ingredient

Tirzepatide

Manufacturer

Eli Lilly India

Dosage 10 mg

Dosage form Prefilled pen

Pens per pack 1

Mounjaro KwikPen 10 — Tirzepatide 10 mg (1 Pen / 4 Doses)

Name: Mounjaro KwikPen 10
Brand: Eli Lilly India
SKU: PROD-270
Price: 22108 UAH
Availability: InStock

22108₴ ~~23388₴~~ -5%

Mounjaro KwikPen 10 mg (Tirzepatide) is a highly effective injectable medication representing a significant breakthrough in the treatment of type 2 diabetes and obesity. Mounjaro is the world's first dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The 10 mg dosage belongs to the category of high therapeutic doses and is prescribed to achieve maximum blood sugar control and intensive body weight reduction.

Manufacturer: Eli Lilly. The KwikPen format is an innovative multi-dose pre-filled pen specifically designed for patient convenience. It ensures high precision in drug administration and minimizes discomfort during injections.

Key Features:

✅ Maximum Efficacy: The 10 mg dose allows for significant improvement in metabolic parameters for patients who do not achieve sufficient results from lower dosages.
✅ Dual Hormone Stimulation: By acting on GIP and GLP-1, the drug not only regulates insulin but also effectively slows gastric emptying, providing a long-lasting feeling of satiety.
✅ Monthly Course in One Pen: The KwikPen device contains 4 ready-to-use doses, making therapy organized and simple.

Mounjaro 10 mg is recommended for use in the following cases:

🔹 Type 2 Diabetes Mellitus: For patients requiring enhanced glycemic control when 5 mg or 7.5 mg doses are ineffective.
🔹 Weight Correction in Obesity: Prescribed to adults with a BMI ≥30 kg/m² or ≥27 kg/m² in the presence of complications (hypertension, dyslipidemia), when the goal is significant fat mass loss and improvement of overall health.

Sales Form: 1 multi-dose KwikPen (2.4 ml of solution) containing 4 doses of 10 mg.

⚠️ INSTRUCTIONS FOR USE:

Dosage Regimen: The drug is administered strictly once a week. The transition to the 10 mg dosage is carried out no earlier than after 4 weeks of using the 7.5 mg dose.
Method of Administration: Subcutaneous injection into the abdomen, thigh, or upper arm. It is recommended to rotate injection sites weekly.
Timing: The injection can be given at any time of day, regardless of meals.
Storage Conditions: Store in the original packaging in the refrigerator at 2°C–8°C. Do not freeze! After starting use (first injection), the pen can be stored at room temperature up to 30°C for 21 days.

⛔ Medullary Thyroid Carcinoma: Personal or family history of this disease in the past.
⛔ Endocrine Pathologies: Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
⛔ Pregnancy and Breastfeeding: Use of the drug is contraindicated.
⛔ Type 1 Diabetes: The drug is not intended for the treatment of insulin-dependent type 1 diabetes.
⛔ GI Diseases: Severe gastroparesis and other serious digestive disorders.
⛔ Age: Safety and efficacy for individuals under 18 years of age have not been established.

When using the 10 mg dosage, side effects may be more pronounced at the beginning of the course:

🤢 Gastrointestinal: Nausea, vomiting, diarrhea, or constipation. These symptoms are usually adaptive and resolve over time.
📉 Appetite Changes: Significant decrease in appetite, aversion to certain foods.
😴 General Condition: Possible drowsiness, increased fatigue, or headache.
💧 Dehydration Risk: If nausea and vomiting occur, it is important to consume enough fluids to protect the kidneys.
⚠️ Serious Complications (rare): Acute pancreatitis, gallbladder problems, hypoglycemia (when combined with insulin or sulfonylureas).